Conference Coverage

Endoscopic ablation follows gastric bypass principles


 

AT THE ADA SCIENTIFIC SESSIONS

References

Dr. Cherrington said the ensuing trials would aim to answer the first question, but that no information on calorie counts was available. The patients experienced an immediate weight loss after DMR but then some rebound effect after that, he said.

Dr. Cherrington disclosed relationships with Biocon, Fractyl, Merck, Metavention, NuSirt Biopharma, Sensulin, Zafgen, Eli Lilly, Silver Lake, Islet Sciences, Novo Nordisk, Profil Institute for Clinical Research, Thermalin Diabetes, Thetis Pharmaceuticals, vTv Therapeutics, ViaCyte, and Viking.

Pages

Recommended Reading

Study plots long-term financial impact of diabetes
MDedge Endocrinology
Empagliflozin slows renal disease progression in type 2 diabetes
MDedge Endocrinology
Pioglitazone safe and effective for steatohepatitis in T2DM
MDedge Endocrinology
Artificial pancreas can improve inpatient glycemic control in type 2 diabetes
MDedge Endocrinology
LEADER: Liraglutide lowers CVD risk in type 2 diabetes
MDedge Endocrinology
Long-term metformin use protective against neurodegenerative disease
MDedge Endocrinology
Benefits of lifestyle intervention only brief in some patients with type 2 diabetes
MDedge Endocrinology
Bariatric surgery good deal for diabetes, but…
MDedge Endocrinology
Long-haul travel turbulent for many with type 1 diabetes
MDedge Endocrinology
Empagliflozin surpasses glimepiride as metformin add-on
MDedge Endocrinology